320 related articles for article (PubMed ID: 32612066)
1. Effects of dapagliflozin on renin-angiotensin-aldosterone system under renin-angiotensin system inhibitor administration.
Isshiki M; Sakuma I; Hayashino Y; Sumita T; Hara K; Takahashi K; Shiojima I; Satoh-Asahara N; Kitazato H; Ito D; Saito D; Hatano M; Ikegami Y; Iida S; Shimada A; Noda M
Endocr J; 2020 Nov; 67(11):1127-1138. PubMed ID: 32612066
[TBL] [Abstract][Full Text] [Related]
2. Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers.
Heerspink HJ; Johnsson E; Gause-Nilsson I; Cain VA; Sjöström CD
Diabetes Obes Metab; 2016 Jun; 18(6):590-7. PubMed ID: 26936519
[TBL] [Abstract][Full Text] [Related]
3. Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin-angiotensin system blockade.
Weber MA; Mansfield TA; Alessi F; Iqbal N; Parikh S; Ptaszynska A
Blood Press; 2016; 25(2):93-103. PubMed ID: 26623980
[TBL] [Abstract][Full Text] [Related]
4. Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes.
Shin SJ; Chung S; Kim SJ; Lee EM; Yoo YH; Kim JW; Ahn YB; Kim ES; Moon SD; Kim MJ; Ko SH
PLoS One; 2016; 11(11):e0165703. PubMed ID: 27802313
[TBL] [Abstract][Full Text] [Related]
5. Plasma renin activity to plasma aldosterone concentration ratio correlates with night-time and pulse pressures in essential hypertensive patients treated with angiotensin-converting enzyme inhibitors/AT1 blockers.
Spannella F; Giulietti F; Balietti P; Borioni E; Lombardi FE; Ricci M; Cocci G; Landi L; Sarzani R
J Hypertens; 2017 Nov; 35(11):2315-2322. PubMed ID: 28614094
[TBL] [Abstract][Full Text] [Related]
6. β-Blocker withdrawal is preferable for accurate interpretation of the aldosterone-renin ratio in chronically treated hypertension.
Browne GA; Griffin TP; O'Shea PM; Dennedy MC
Clin Endocrinol (Oxf); 2016 Mar; 84(3):325-31. PubMed ID: 26300226
[TBL] [Abstract][Full Text] [Related]
7. Effect of SGLT2 inhibitors on body composition, fluid status and renin-angiotensin-aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy.
Schork A; Saynisch J; Vosseler A; Jaghutriz BA; Heyne N; Peter A; Häring HU; Stefan N; Fritsche A; Artunc F
Cardiovasc Diabetol; 2019 Apr; 18(1):46. PubMed ID: 30953516
[TBL] [Abstract][Full Text] [Related]
8. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.
Wheeler DC; Stefansson BV; Batiushin M; Bilchenko O; Cherney DZI; Chertow GM; Douthat W; Dwyer JP; Escudero E; Pecoits-Filho R; Furuland H; Górriz JL; Greene T; Haller H; Hou FF; Kang SW; Isidto R; Khullar D; Mark PB; McMurray JJV; Kashihara N; Nowicki M; Persson F; Correa-Rotter R; Rossing P; Toto RD; Umanath K; Van Bui P; Wittmann I; Lindberg M; Sjöström CD; Langkilde AM; Heerspink HJL
Nephrol Dial Transplant; 2020 Oct; 35(10):1700-1711. PubMed ID: 32862232
[TBL] [Abstract][Full Text] [Related]
9. Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial.
Heerspink HJL; Stefansson BV; Chertow GM; Correa-Rotter R; Greene T; Hou FF; Lindberg M; McMurray J; Rossing P; Toto R; Langkilde AM; Wheeler DC;
Nephrol Dial Transplant; 2020 Feb; 35(2):274-282. PubMed ID: 32030417
[TBL] [Abstract][Full Text] [Related]
10. Influence of salt intake on target organ damages in treated hypertensive patients.
Ohta Y; Tsuchihashi T; Kiyohara K
Clin Exp Hypertens; 2012; 34(5):316-20. PubMed ID: 22804491
[TBL] [Abstract][Full Text] [Related]
11. Effects of dapagliflozin on volume status and systemic haemodynamics in patients with chronic kidney disease without diabetes: Results from DAPASALT and DIAMOND.
Sen T; Scholtes R; Greasley PJ; Cherney DZI; Dekkers CCJ; Vervloet M; Danser AHJ; Barbour SJ; Karlsson C; Hammarstedt A; Li Q; Laverman GD; Bjornstad P; van Raalte DH; Heerspink HJL
Diabetes Obes Metab; 2022 Aug; 24(8):1578-1587. PubMed ID: 35478433
[TBL] [Abstract][Full Text] [Related]
12. Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects.
Blumenfeld JD; Sealey JE; Mann SJ; Bragat A; Marion R; Pecker MS; Sotelo J; August P; Pickering TG; Laragh JH
Am J Hypertens; 1999 May; 12(5):451-9. PubMed ID: 10342782
[TBL] [Abstract][Full Text] [Related]
13. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.
Pollock C; Stefánsson B; Reyner D; Rossing P; Sjöström CD; Wheeler DC; Langkilde AM; Heerspink HJL
Lancet Diabetes Endocrinol; 2019 Jun; 7(6):429-441. PubMed ID: 30992195
[TBL] [Abstract][Full Text] [Related]
14. Slowing Progression in CKD: DAPA CKD and Beyond.
Larmour K; Levin A
Clin J Am Soc Nephrol; 2021 Jul; 16(7):1117-1119. PubMed ID: 33692116
[No Abstract] [Full Text] [Related]
15. Does SGLT2 inhibition with dapagliflozin overcome individual therapy resistance to RAAS inhibition?
Petrykiv S; Laverman GD; de Zeeuw D; Heerspink HJL
Diabetes Obes Metab; 2018 Jan; 20(1):224-227. PubMed ID: 28685934
[TBL] [Abstract][Full Text] [Related]
16. Relationship between urinary sodium excretion and serum aldosterone in patients with diabetes in the presence and absence of modifiers of the renin-angiotensin-aldosterone system.
Libianto R; Jerums G; Lam Q; Chen A; Baqar S; Pyrlis F; Macisaac RJ; Moran J; Ekinci EI
Clin Sci (Lond); 2014 Jan; 126(2):147-54. PubMed ID: 23875766
[TBL] [Abstract][Full Text] [Related]
17. Albuminuria-Lowering Effect of Dapagliflozin, Eplerenone, and Their Combination in Patients with Chronic Kidney Disease: A Randomized Crossover Clinical Trial.
Provenzano M; Puchades MJ; Garofalo C; Jongs N; D'Marco L; Andreucci M; De Nicola L; Gorriz JL; Heerspink HJL; ;
J Am Soc Nephrol; 2022 Aug; 33(8):1569-1580. PubMed ID: 35440501
[TBL] [Abstract][Full Text] [Related]
18. Effect of Sodium Glucose Co-Transporter-2 Inhibition on the Aldosterone/Renin Ratio in Type 2 Diabetes Mellitus.
Griffin TP; Islam MN; Blake L; Bell M; Griffin MD; O'Shea PM
Horm Metab Res; 2019 Feb; 51(2):91-99. PubMed ID: 30522145
[TBL] [Abstract][Full Text] [Related]
19. Plasma aldosterone is increased in class 2 and 3 obese essential hypertensive patients despite drug treatment.
Sarzani R; Guerra F; Mancinelli L; Buglioni A; Franchi E; Dessì-Fulgheri P
Am J Hypertens; 2012 Jul; 25(7):818-26. PubMed ID: 22552267
[TBL] [Abstract][Full Text] [Related]
20. Competing Effects of Renin Angiotensin System Blockade and Sodium-Glucose Cotransporter-2 Inhibitors on Erythropoietin Secretion in Diabetes.
Marathias KP; Lambadiari VA; Markakis KP; Vlahakos VD; Bacharaki D; Raptis AE; Dimitriadis GD; Vlahakos DV
Am J Nephrol; 2020; 51(5):349-356. PubMed ID: 32241009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
